NasdaqGS - Delayed Quote USD

Seres Therapeutics, Inc. (MCRB)

0.9199 -0.0045 (-0.49%)
At close: May 17 at 4:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
126,847.0000
126,325.0000
7,128.0000
144,927.0000
33,215.0000
Operating Expense
203,848.0000
234,308.0000
253,618.0000
209,420.0000
121,345.0000
Operating Income
-77,001.0000
-107,983.0000
-246,490.0000
-64,493.0000
-88,130.0000
Net Non Operating Interest Income Expense
-7,974.0000
-5,875.0000
-2,962.0000
-40.0000
-1,978.0000
Other Income Expense
2,292.0000
134.0000
-705.0000
-1,045.0000
981.0000
Pretax Income
-82,683.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Net Income Common Stockholders
-82,683.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Diluted NI Available to Com Stockholders
-82,683.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Basic EPS
-0.59
--
-2.31
-0.72
-1.12
Diluted EPS
-0.59
--
-2.31
-0.72
-1.12
Basic Average Shares
133,062.9460
--
108,077.0430
91,702.8660
79,789.2200
Diluted Average Shares
133,062.9460
--
108,077.0430
91,702.8660
79,789.2200
Total Operating Income as Reported
-77,001.0000
-107,983.0000
-246,490.0000
-64,493.0000
-88,130.0000
Total Expenses
203,848.0000
234,308.0000
253,618.0000
209,420.0000
121,345.0000
Net Income from Continuing & Discontinued Operation
-82,683.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Normalized Income
-82,683.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Interest Income
7,917.0000
7,301.0000
3,058.0000
2,870.0000
946.0000
Interest Expense
15,891.0000
13,176.0000
6,020.0000
2,910.0000
2,924.0000
Net Interest Income
-7,974.0000
-5,875.0000
-2,962.0000
-40.0000
-1,978.0000
EBIT
-66,792.0000
-100,548.0000
-244,137.0000
-62,668.0000
-86,203.0000
EBITDA
-60,390.0000
-94,305.0000
-237,508.0000
-56,721.0000
-79,625.0000
Reconciled Depreciation
6,402.0000
6,243.0000
6,629.0000
5,947.0000
6,578.0000
Net Income from Continuing Operation Net Minority Interest
-82,683.0000
-113,724.0000
-250,157.0000
-65,578.0000
-89,127.0000
Normalized EBITDA
-60,390.0000
-94,305.0000
-237,508.0000
-56,721.0000
-79,625.0000
12/31/2020 - 6/26/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AKBA Akebia Therapeutics, Inc.
1.1500
+0.88%
 
XFOR X4 Pharmaceuticals, Inc.
0.9284
-3.26%
 
ARDX Ardelyx, Inc.
7.82
+0.32%
 
ALT Altimmune, Inc.
8.01
-10.00%
 
IOVA Iovance Biotherapeutics, Inc.
10.24
-1.82%
 
CTMX CytomX Therapeutics, Inc.
1.8900
-5.50%
 
SGMO Sangamo Therapeutics, Inc.
0.6496
+6.72%
 
BLUE bluebird bio, Inc.
1.0300
-1.90%
 
SCPH scPharmaceuticals Inc.
4.7500
-1.55%
 
RAPT RAPT Therapeutics, Inc.
4.0400
-2.42%